Samjin pharm said on the 13th that it received export approval from Philippine health authorities for the antithrombotic drug "Pleris tablets."
Pleris tablets contain clopidogrel hydrogen sulfate and are used to treat cardiovascular, cerebrovascular, and peripheral arterial diseases. They can be prescribed as monotherapy or in combination therapy at most tertiary general hospitals in Korea.
Samjin pharm is developing Pleris tablets as a flagship prescription drug. Focusing on research and development (R&D) after its 2007 launch, the company in 2009 succeeded in independently synthesizing "spherical particle-type clopidogrel hydrogen sulfate," the active ingredient in Pleris, for the first time in Korea. Because this synthesis technology is highly complex, only one or two places in the world possess it.
Starting with Pleris tablets, the company will diversify its product lineup in the Philippine market. Additional export talks are underway for the anticoagulant "Elsaban tablets" and the anticancer drug "Petra tablets," among others, and among them, Elsaban tablets also received export approval in Azerbaijan this year.
President Kim Sang-jin of Samjin pharm said, "The entry of the antithrombotic drug 'Pleris tablets' into the Philippines is an important achievement for Samjin pharm's future global leap," adding, "We will use this as a bridgehead to continue expanding exports of key medicines to global markets."